Compare IPGP & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPGP | APLS |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.2B |
| IPO Year | 2000 | 2015 |
| Metric | IPGP | APLS |
|---|---|---|
| Price | $101.67 | $41.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 21 |
| Target Price | ★ $131.40 | $33.59 |
| AVG Volume (30 Days) | 586.5K | ★ 6.7M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 117.85 | 112.50 |
| EPS | 0.04 | ★ 0.15 |
| Revenue | $1,003,777,000.00 | ★ $1,003,782,000.00 |
| Revenue This Year | $12.18 | N/A |
| Revenue Next Year | $8.44 | $18.19 |
| P/E Ratio | $2,625.50 | ★ $273.60 |
| Revenue Growth | 2.73 | ★ 28.46 |
| 52 Week Low | $63.33 | $16.61 |
| 52 Week High | $155.82 | $41.14 |
| Indicator | IPGP | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 84.57 |
| Support Level | $76.61 | $19.29 |
| Resistance Level | $129.39 | $41.14 |
| Average True Range (ATR) | 5.71 | 0.06 |
| MACD | -0.85 | -0.65 |
| Stochastic Oscillator | 39.04 | 58.33 |
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, laser and non-laser systems, fiber amplifiers, diode lasers, and related optical components. Its products are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company sells its products globally to original equipment manufacturers (OEMs), system integrators, and end users. Additionally, it manufactures complementary products used with its lasers, including optical delivery cables, fiber couplers, beam switches, optical processing heads, in-line sensors, and chillers. Geographically, the company generates maximum revenue from North America, followed by China, Japan, Germany, and other markets.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).